Ken Griffin Neurocrine Biosciences Inc Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$111.62 - $139.44 $658,558 - $822,696	5,900 Added 12.55%	52,900 $7.22 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $1.23 Million - $1.64 Million	10,700 Added 29.48%	47,000 $5.41 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $353,322 - $386,613	-2,700 Reduced 6.92%	36,300 $5 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $65,200 - $71,870	-500 Reduced 1.27%	39,000 $5.38 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $2.99 Million - $3.74 Million	-28,200 Reduced 41.65%	39,500 $5.2 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $3.73 Million - $4.65 Million	39,700 Added 141.79%	67,700 $7.62 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $277,543 - $325,097	3,100 Added 12.45%	28,000 $2.64 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $2.14 Million - $2.79 Million	-22,700 Reduced 47.69%	24,900 $2.52 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $1.9 Million - $2.26 Million	17,800 Added 59.73%	47,600 $5.69 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $3.88 Million - $4.55 Million	-42,200 Reduced 58.61%	29,800 $3.17 Million

655

95.9M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $9.08B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.